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ABSTRACT
Signaling through the mammalian target of
rapamycin, complex 1 (mTORC1), positively regu-
lates the transcription of ribosomal RNA (rRNA)
and the synthesis of ribosomal proteins, thereby
promoting the complex process of ribosome bio-
genesis. The major rRNAs are transcribed as a
single precursor, which must be processed to
create the 5.8S, 18S and 28S rRNAs. We used a
new non-radioactive labeling approach to study
the effects of rapamycin, an inhibitor of mTORC1,
on rRNA synthesis. Rapamycin not only impaired
synthesis of new 18S, 28S or 5S rRNA but also
induced their decay. This prompted us to examine
the effects of rapamycin on rRNA processing. We
show that rapamycin also interferes with the pro-
cessing events that generate 18S and 28S rRNA.
rRNA transcription and processing occur in
regions of the nucleus known as nucleoli. We find
that the mTORC1 components raptor and mTOR are
both present in nucleoli, where they may regulate
rRNA maturation events. While rapamycin has no
effect on overall nucleolar morphology or its
proteome, it does induce loss of mTOR and raptor
from them. These data show that mTORC1 is
located in nucleoli where it acts to regulate events
involved in ribosome biogenesis including the mat-
uration of rRNA molecules.
INTRODUCTION
Signaling through the mammalian target of rapamycin
(complex 1), mTORC1, regulates many diverse cellular
processes, especially those contributing to cell growth
and proliferation (1), including the production of ribo-
somes (2). This process, termed ribosome biogenesis, is a
complex one that involves the synthesis and subsequent
processing of 4 different ribosomal RNAs (rRNAs) and
around 80 proteins, which are assembled into ribosomes in
the nucleolus, aided by many additional proteins and
small RNAs. mTORC1 signaling promotes the transcrip-
tion of the 47S precursor by positively regulating Pol I
[which makes three of the rRNAs, (3)] and the translation
of the mRNAs encoding ribosomal proteins (4).
Ribosome biogenesis is critical for maintaining cells’
capacity for protein synthesis, especially during cell
growth (hypertrophy) or proliferation. Indeed, increases
in the size and number of nucleoli have long been
recognized as a key feature of cancer cells (5).
Furthermore, deregulation of ribosome biogenesis may
pre-dispose toward cancer and other conditions (6,7).
Defective ribosome biogenesis can also activate the
tumor suppressor p53 and/or induce apoptosis (8,9).
Three of the rRNAs, 5.8S, 18S and 28S, are transcribed
as a single precursor (47S) by RNA polymerase I (Pol I) in
the nucleolus, which is then processed through several
steps to generate the mature rRNAs. Here, we show
for the ﬁrst time that rapamycin interferes with the pro-
cessing of rRNA in human cells indicating that mTORC1
signaling controls pre-rRNA processing in addition to the
synthesis of rRNA and ribosomal proteins. Furthermore,
we show that mTORC1 is present in the nucleolus and this
localization is disrupted by rapamycin. This likely allows
mTORC1, which is recognized as a positive regulator of
anabolic cellular functions, to promote and coordinate the
complex multiplicity of steps involved in manufacturing
new ribosomes.
MATERIALS AND METHODS
Cell culture and reagents
Human cervical carcinoma HeLa cells were grown in
Dulbecco’s modiﬁed Eagle medium (DMEM) supple-
mented with 10% (v/v) fetal calf serum (FCS), 100U/ml
of penicillin and 100mg/ml streptomycin in 5% CO2 at
37 C.
4-Thiouridine (4-TU) was used at 100mM (Sigma
T4509), actinomycin D (Sigma, A1410) was used at the
concentrations given in the text. Rapamycin (Calbiochem
553210) was used at 100nM (unless stated otherwise) and
*To whom correspondence should be addressed. Tel: +44 023 80592028; Fax: +44 2380 585159; Email: c.g.proud@soton.ac.uk
Published online 24 November 2011 Nucleic Acids Research, 2012, Vol. 40, No. 6 2527–2539
doi:10.1093/nar/gkr1040
 The Author(s) 2011. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.for the times indicated in the legends. AZD8055 was
kindly provided by AstraZeneca UK.
RNA preparation and biotinylation of 4-TU-labeled RNA
The procedure for labeling newly synthesized RNA within
cells using modiﬁed uridine was adapted from those
described earlier (10,11). Total RNA was extracted from
HeLa cells using Trizol (Invitrogen, 15596-018) following
the manufacturer’s protocol.
To biotinylate 4-TU-labeled RNA, total RNA was
incubated with EZ-Link Biotin-HPDP (Pierce 21341).
Biotin-HPDP was suspended in dimethylformamide at a
concentration of 1mg/ml. One microliter of this reagent
was used per 1mg of RNA extracted from the labeling
reaction. Biotinylation of 4-TU-labeled RNA was per-
formed in 10mM Tris–HCl (pH 7.5) and 1mM EDTA
in a ﬁnal volume ﬁve times greater than that of
biotin-HPDP in the reaction. RNA was then incubated
with biotin-HPDP at room temperature for 2h in the
dark. To precipitate RNA, 1/10 of the reaction volume
of 5M NaCl and equal reaction volume of isopropanol
were added and the sample was centrifuged at 14500rpm
for 20min. The pellet was rinsed with 75% (v/v) ethanol
and resuspended in RNase-free water. The samples were
stored at  80 C until required.
Isolation of 4-TU-labeled RNA from total RNA
To purify 4-TU-labeled RNA, Magnetic Porous Glass
(MPG) streptavidin beads (PUREBiotech MSTR0510)
were used to capture the biotinylated RNA. One micro-
liter of MPG streptavidin beads was used per microgram
of total RNA. The beads were incubated with carrier
yeast tRNA (1mg tRNA per 5ml beads) for 20min at
ambient temperature to prevent non-speciﬁc binding and
washed three times in 500ml MPG Buffer (1M NaCl,
10mM EDTA, 100mM Tris–HCl, pH 7.5) before
adding RNA. MPG beads were collected in a magnetic
stand and resuspended in MPG buffer to the original
volume of beads. The volume of biotinylated RNA
sample was adjusted with RNase-free water to the
same volume as the beads. The biotinylated RNA was
then added to the beads and incubated at ambient tem-
perature for 1h with rotation. The beads were collected
on the magnetic stand for more than 1min and followed
by washing three times in 500ml MPG buffer, the ﬁrst
two times at ambient temperature and the last one at
65 C. Two more washes were performed at ambient tem-
perature to make sure that all the non-4-TU-labeled
RNA was washed away. Bound RNA that was labeled
by 4-TU was eluted by suspending the MPG beads in
freshly diluted 5% b-mercaptoethanol volume equal to
that of the original beads. The mixture was incubated at
room temperature for at least 20min with rotation. The
beads were collected on the magnetic stand for about
1min and the supernatant was saved. One microgram
of glycogen (Roche #10901393 001) were added as car-
rier and RNA was precipitated using isopropanol and
NaCl. The pellet was rinsed with 75% (v/v) ethanol
and resuspended in RNase-free water. The resuspended
RNA sample was then placed in magnetic stand for
>1min to collect any excess beads from earlier steps.
The supernatant was transferred to a new tube; this
sample contains puriﬁed 4-TU-labeled RNA.
RT–PCR ampliﬁcation analysis
Total puriﬁed 4-TU-labeled RNA was treated with
RNase-free DNAse (optional Roche Cat. No.
04716728001) and then subjected to SuperScript III
reverse transcription (Invitrogen #18080-044) with an
oligo(dT)15 primer (Invitrogen #18418-012) and random
primers (Invitrogen #48190-011) following the manufac-
turer’s protocol. Subsequently, PCR using speciﬁc primers
(PrimerDesign HY-SY-hu-600) was employed to amplify
18S rRNA and other house-keeping genes according to
the product protocol. The comparative Ct method was
employed to measure ampliﬁcation of the new rRNAs
from control and treated samples. The quantity of new
(labeled) rRNA was normalized to the total amount of
18S rRNA in this sample before the pulldown. These
data were compared with the corresponding data for
untreated cells and the results are expressed as, e.g.,
‘new 18S rRNA/control’.
Uridine uptake
Uridine transport was monitored in cultured HeLa cells in
medium either containing or lacking Na
+ ions, using a
method based on those used in earlier studies (12,13).
The medium contained 5.4mM KCl, 1.8mM CaCl2,
1.2mM MgSO4, 10mM HEPES (pH 7.4) and 137mM
Choline chloride and [
3H]uridine (1mCi/nmol). After
20-s incubation, uptake was stopped by washing three
times in 2ml of ice-cold transport buffer containing
1mM unlabeled competitor uridine and two inhibitors
of nucleoside uptake, 1mM S-(4-Nitrobenzyl)-
6-thioinosine (Sigma N2255) and dipyridamole (Sigma
D9766). Cells were lysed in 500ml of a solution containing
0.5% Triton X-100 and 100mM NaOH before quantiﬁ-
cation of radioactivity by scintillation counting, data
being corrected to disintegrations per minute.
Immunoﬂuorescence microscopy
HeLa cells were grown on coverslips in complete DMEM/
FCS for 15h, and then incubated with rapamycin or
actinomycin D for 2h. Cells were washed twice in
phosphate-buffered saline (PBS), ﬁxed with formaldehyde
(4% in PBS) for 15min at ambient temperature,
permeabilized with PBS/Triton X-100 0.1% for 10min
and blocked with 1% bovine serum albumin in PBS
for 1h.
Antibodies for nucleophosmin/B23 were from Sigma
(FC82291) and for block of proliferation1 (BOP1) from
BioVaria. Primary antibodies were incubated for 2h at
room temperature. After washing in PBS, labeled second-
ary antibodies (rhodamine-conjugated AfﬁniPure donkey
anti-mouse IgG, Jackson ImmunoResearch) were
incubated at room temperature for 2h in the dark at
room temperature. Cells were washed with PBS and
nuclei were counterstained with TO-PRO-3 (Invitrogen,
T3605) 1:1000 for 15min at room temperature in dark.
Coverslips were mounted with 50ml of ProLong Gold
2528 Nucleic Acids Research, 2012,Vol.40, No. 6anti-fade (Invitrogen, P36930) overnight in the dark at
room temperature.
RNA preparation, northern blot and pre-rRNA species
Total RNA was extracted by the proteinase K method
(14). For the northern blot analysis, RNA (5mg) was
fractionated on agarose-formaldehyde gels 1.5% and
transferred to GeneScreen Plus membrane (PerkinElmer
Life Sciences) for 15h. Northern blotting was performed
essentially as recommended by the manufacturer.
Oligonucleotides were end-labeled with [g-
32P]ATP and
T4 polynucleotide kinase (BioLabs M0201S) for
30min at 37 C. Membranes were hybridized overnight
in hybridization buffer [6X SSPE, 5X Denhardt’s
solution, 0.1mg/ml ﬁsh sperm DNA and 1% sodium
dodecyl sulfate (SDS)]. Washing was performed in 2X
SSPE, 1% SDS at 65 C for 30min. Membranes were
exposed to storage phosphor screen (GE-Healthcare)
and analyzed using a Phosphorimager (STORM, GE
Healthcare). Quantitation of northern blots was per-
formed using the Image-Quant software (Amersham
Biosciences).
Polysome analysis
HeLa cells were lysed with 300ml of lysis buffer [10 mM
NaCl, 10mM MgCl2, 10mM Tris–HCl, pH 7.5, 1% (v/v)
Triton X-100, 1% sodium deoxycholate, 36U/ml RNase
inhibitor, 1mM dithiothreitol] and layered in a 20–50%
sucrose gradient containing 30mM Tris–HCl, pH 7.5,
100mM NaCl and 10mM MgCl2, and centrifuged in
a Beckman SW41 rotor for 150min at 37000rpm
(234,000 rcf). Fractions were collected while monitoring
absorbance at 254nm. RNA was extracted from each
fraction and northern blot were performed as previously
described (15). Radioactive probes were prepared by the
random primer technique. Quantitation of northern blots
was performed using a PhosphorImager and Image-Quant
software (GE Healthcare).
Oligonucleotides
The oligonucleotide sequences complementary to the
human rDNA used were:
ITS1: 50-CCTCGCCCTCCGGGCTCCGTTAATTGA
TC-30 (16)
ITS2: 50-CGCACCCCGAGGAGCCCGGAGGCACCC
CCGG-30 (17)
18S: 50-CACCCGTGGTCACCATGGTAGGCACGGC
GACTACCATCGAAAGTTGATAG-30
28S: 50-CCAGCTATCCTGAGGGAAACTTCGGAGG
GAACCAGCTACTAGATGGTTCG-30
Subcellular fractionation
To prepare total cell extracts, HeLa cells were washed
twice with cold PBS and then lysed in high salt buffer
[50mM Tris HCl pH 7.5, 350mM NaCl, 1mM MgCl2,
0.5mM EDTA, 0.1mM EGTA and 1% (v/v) Triton
X-100] supplemented with protease inhibitor cocktail
tablet (mini EDTA-free complete protease inhibitor
cocktail tablet, Roche 11873580001). The cell lysate was
incubated on ice for 30min and centrifuged at 14500rpm
for 10min at 4 C.
For the fractionation of nuclei and cytoplasm, HeLa
cells were washed twice with cold PBS and resuspended
in cold buffer A comprising 10mM Tris–HCl pH 7.5,
10mM NaCl, 3mM MgCl2, 0.05% of Nonidet P-40 and
protease inhibitor. The cell lysates were centrifuged at
700rpm for 5min at 4 C. After removal of the super-
natant (the cytoplasmic fraction), the resulting pellet (the
nuclear fraction) was washed ﬁve to six times with buffer
A and resuspended in cold buffer B containing 20mM
Tris–HCl pH 7.5, 420mM NaCl, 1.5mM MgCl2,1 m M
EDTA, 1mM EGTA, 20% (v/v) glycerol, 1% (v/v)
Nonidet P-40 and protease inhibitors. The nuclear
extract was incubated for 1h at 4 C on a rotating tube
mixer. It was then centrifuged for 10min at 13000rpm
(rcf 15700) at 4 C and the supernatant was carefully
removed and stored at  20 C. Nucleoli were isolated as
described (18).
Western blotting and antibodies
Protein concentrations were determined by Bradford
reagent. Cell lysate was heated at 95 C for 5min in
sample buffer [62.5mM Tris–HCl, 7% (w/v) SDS, 20%
(w/v) sucrose and 0.01% (w/v) bromophenol blue] and
subjected to polyacrylamide gel electrophoresis and elec-
trophoretic transfer to nitrocellulose membranes.
Membranes were then blocked in PBS–Tween containing
5% (w/v) skimmed milk powder for 30min at room tem-
perature. The membranes were probed with the indicated
primary antibody overnight at 4 C. Antibodies speciﬁc for
the following proteins were used: mTOR (Cell Signaling
Technology, #2972), raptor (Cell Signaling Technology
#4978), Lamin B (Santa Cruz sc-6216), glyceraldehyde
3-phosphate dehydrogenase (GAPDH; Abcam ab9485),
histone H3 (Millipore, 06.755), phospho-S6 ribosomal
protein Ser235/236 and Ser240/244 (Cell Signaling
Technology, #5316 and #2215), ribosomal protein
(Rp)S6 (Cell Signaling Technology, #2317), Pes1
(Abnova B02), p70 S6 kinase (Cell Signaling
Technology, #9202) and UBF (Santa Cruz, sc-9131).
The antibody for S6K2 was a kind gift from Professor
Ivan Gout (University College, London). After incubation
with ﬂuorescently tagged secondary antibody, the signals
were scanned using a Licor Odyssey imaging system.
RESULTS
Rapamycin induces the decay of new rRNA molecules
We used a novel approach to study the synthesis of new
rRNA molecules, in which they are labeled, in vivo, with
4-thiouridine (4-TU), allowing them subsequently to be
biotinylated, speciﬁcally puriﬁed and subjected to reverse
transcription (10,11). The resulting cDNA can then be
used as the template for quantitative real-time PCR to
determine levels of any speciﬁc RNA (Figure 1A and B
illustrates the overall procedure). This new approach
offers several important advantages over earlier methods
using, e.g. [
14C]orotic acid to radiolabel new rRNA. In
Nucleic Acids Research,2012, Vol.40, No. 6 2529addition to avoiding the use of radioactivity, it allows
one easily to quantify speciﬁc RNA components by
using appropriate qPCR primers, thus obviating the
need to run gels to resolve individual rRNA or
pre-rRNA species and can readily be conﬁgured as a
pulse-chase experiment (see below) without complications
due to loss of label due to excision of rRNA fragments
during processing.
Figure 1C shows that 4-TU is incorporated into 18S
rRNA in HeLa cells, and that, as expected, this is
almost totally inhibited by low concentrations of
actinomycin D. Label was also incorporated into 5S
rRNA (Figure 1D) and this was also partially inhibited
by actinomycin D. Consistent with the lower sensitivity of
RNA polymerase III to actinomycin D, higher concentra-
tions were needed to achieve strong inhibition of labeling
of 5S rRNA. Taken together, the sensitivity of the labeling
to actinomycin D indicates that labeling is dependent
upon ongoing transcription, i.e. reﬂects new rRNA
synthesis.
One potential concern was that, as with any labeling
technique applied to intact cells, the signaling inhibitors
to be used might interfere with the uptake of the label into
the cells in addition to affecting, in this case, RNA syn-
thesis by impairing relevant signaling events. Rapamycin
is a highly speciﬁc inhibitor of mTORC1 when used at
high concentrations (19), but has been reported to
impair the transport of nucleotides into mammalian cells
(20). To try to minimize such effects, we tested the ability
of a range of concentrations to inhibit mTORC1 signaling
in HeLa cells, monitoring the phosphorylation of riboso-
mal protein (RpS6) at Ser240/244 as a readout [these
residues are speciﬁc targets of the S6 kinases which lie
downstream of mTORC1 (21)]. As shown in Figure 2A,
Figure 1. Procedure used to label newly synthesized RNA molecules with 4-TU. (A) Flow chart and (B) scheme showing the labeling of new RNAs
with 4-TU, followed by derivatization with biotin and puriﬁcation of tagged RNAs. After reverse transcription, any individual cDNA (RNA) species
can be quantitated by qPCR. (C and D) HeLa cells were pre-cultured with actinomycin D for 30min at different concentrations, as indicated (high:
2mg/ml or low: 20ng/ml), and then the cells were incubated with 4-TU 100nM for 3h. 4-TU-labeled RNAs were extracted and puriﬁed as described
in the ‘Materials and Methods’ section. The amounts of cDNAs derived from speciﬁc RNAs were quantitated by RT–qPCR and are expressed as
described in the ‘Materials and Methods’ section: (C) Data for 18S rRNA (also measures its precursors); (B) Data for 5S rRNA.
2530 Nucleic Acids Research, 2012,Vol.40, No. 6concentrations as low as 1nM rapamycin could inhibit
RpS6 phosphorylation, although maximal inhibition was
only consistently seen at 5nM. Even at 5nM, rapamycin
inhibited the uptake of radio-labeled [
3H]uridine into
HeLa cells (Figure 2B); higher concentrations of
rapamycin inhibited to a similar extent (data not
shown). This effect needs to be taken into account when
measuring RNA synthesis using 4-TU or other labeled
nucleoside precursors. On the other hand, for pulse-chase
experiments, of the type used here to study RNA stability,
this effect of rapamycin on nucleoside uptake is not an
issue (as discussed below). It should be noted that for
the uridine uptake experiments, we took care to
pre-treat the cells with rapamycin for a period correspond-
ing to the longest time of exposure for the 4-TU incorp-
oration experiments as described below.
We then studied the effects of rapamycin on the synthe-
sis and stability of rRNA using the 4-TU-labeling proced-
ure. It should be noted that these short times of rapamycin
treatment (2–6h) are insufﬁcient to affect cell-cycle pro-
gression. Rapamycin inhibited the labeling of newly
synthesized 18S or 5S rRNA at 45min and completely
inhibited further incorporation up to 90min of labeling
(Figure 2C and D), which appears consistent with
several lines of evidence showing that signaling through
mTORC1, or equivalent complexes in other species,
promotes rRNA synthesis [reviewed in (2)]. While the
reduced level of labeling at 45min almost certainly
reﬂects, at least in part, impaired uptake of label into
the cells, the absence of a further increase in labeled
rRNA at 90min indicates a strong block in new rRNA
synthesis over and beyond any impairment of uptake. In
fact, and surprisingly, in rapamycin-treated cells, the
labeling of all three rRNAs was actually lower at the
later time-point than at the earlier one (Figure 2C), sug-
gesting that rapamycin may induce the degradation of new
rRNA. Similar data were obtained using rapamycin at
5nM or 100nM (Figure 2C and D), the latter concentra-
tion being the one we have employed previously to study
mTORC1 signaling [see e.g. (22,23)].
One advantage of the 4-TU-labeling approach is that it
can readily be conﬁgured as a pulse-chase experiment
(Figure 2E), where new RNA is labeled with 4-TU and
the medium is then changed to one lacking 4-TU, adding
e.g. rapamycin and the incubation is continued. In this
format, the effect of, e.g. rapamycin on nucleoside
uptake is not relevant, as rapamycin is only added after
switching to label-free medium. Using this method, no loss
of new 18S or 5S rRNA was seen after the end of the pulse
in control cells, while, in contrast, rapamycin-induced
rapid loss of 4-TU-labeled 18S or 5S rRNA (Figure 2E),
indicating that rapamycin induces the decay of newly
made rRNA.
Since 18S rRNA is derived from a single precursor that
also contains the 28S rRNA, it seemed likely that
rapamycin might also induce decay of new 28S rRNA.
Using the same approach, we did indeed observe that
rapamycin caused the loss of newly made (4-TU-labeled)
28S rRNA (data not shown). Taken together, these data
suggest that rapamycin might interfere with the
downstream processing of new rRNA molecules resulting
in their degradation.
Interestingly, rapamycin also induced the decay of
newly made 5S rRNA (Figure 2D and E), although this
rRNA does not require processing. This may reﬂect the
inhibition by rapamycin of the overall process of ribosome
assembly, indicating that impaired ribosome biogenesis
affects 5S rRNA stability. This type of effect may also
explain why low concentrations of actinomycin D partial-
ly impair the accumulation of new 5S rRNA (Figure 1D),
even though at this concentration it has little direct inhibi-
tory effect on Pol III.
Rapamycin also affects rRNA processing
To study rRNA processing, we used northern blot analysis
employing two different probes (ITS1/2) that recognize
distinct regions of the 47S rRNA precursor (for details,
see Figure 3A). Using the ITS1 probe, it is clear that
rapamycin causes a marked increase in the amount of
the 30S pre-rRNA, which is a precursor of the 18S
rRNA (Figure 3B and C). This is especially apparent
after 6-h rapamycin treatment, but is evident as early as
2h. A modest increase in the 21S species was also
observed in response to treatment with rapamycin
indicating that mTORC1 signaling likely affects the con-
version of the 30S to the 21S pre-rRNA. Similar analysis
with the ITS2 probe revealed that treatment with
rapamycin for 6h also caused an accumulation of the
32S pre-rRNA species, the precursor of 5.8S and 28S
rRNA (Figure 3D and E), indicating that mTORC1 sig-
naling impacts on both major ‘arms’ of 47S pre-rRNA
processing. Thus, inhibition of mTORC1 impairs the pro-
cessing of 30S to 21S rRNA and also the conversion of
32S to 12S pre-rRNA and 28S rRNA (Figure 3B and C),
with the former being affected more quickly by
rapamycin. The accumulation of the 32S and 30S
pre-rRNA species was more pronounced after 6h
rapamycin treatment than after 2h (Figure 3D and E
and cf. Figure 3B and C).
Since inhibition of rRNA transcription would result in
the loss of early intermediates in the pathway of rRNA
processing, whereas we actually observe an increase in
their levels (Figure 3B and D), the effects of rapamycin
onprocessingcannotmerelybeaconsequence ofinhibition
of rRNA transcription. This is consistent with the effects of
low concentrations of actinomycin D (which potently
inhibitPolI;Figure1CandD)ontheprocessingintermedi-
ates that are quite different from those of rapamycin
(Figure 3B and C): as expected, actinomycin D caused a
loss of processing intermediates, reﬂecting blocked Pol I
transcription. Thus, mTORC1 signaling regulates the pro-
cessing of pre-rRNA, affecting at least two steps in this
process, the conversion of 30S to 21S and the processing
of 32S rRNA, in the pathways that lead to 18S and
28S+5.8S rRNAs, respectively (as indicated in Figure 3A).
It was also of interest to assess whether a different type
of mTOR inhibitor also impaired the processing of rRNA.
AZD8055 inhibits mTOR by acting as a competitive
inhibitor of its kinase activity (24), unlike rapamycin,
which is an allosteric inhibitor. As shown in Figure 3D,
Nucleic Acids Research,2012, Vol.40, No. 6 2531AZD8055 treatment also led to the accumulation of the
30S and 32S species, although the build up of the 32S
species was less pronounced than for rapamycin.
Interestingly, AZD8055 also caused a modest but repro-
ducible decrease in the amount of the 18S-E species,
indicating that it also blocks further processing of the
21S intermediate, which rapamycin does not appear to
do. These data indicate that inhibition of mTOR kinase
activity, like rapamycin, impairs pre-rRNA processing,
but also suggest qualitative differences. This is also clear
Figure 2. Rapamycin inhibits the accumulation of new rRNA and promotes its decay. (A) HeLa cells maintained in medium containing serum were
treated with or without rapamycin at the indicated concentrations for 90min. Levels of phosphorylated and total RpS6 were analyzed by western
blot; data are typical of three separate experiments. (B) Uridine uptake was measured after 20s incubation with [
3H]uridine in the absence or
presence of 5nM rapamycin (added 90min prior to the uptake assay). The radioactivity was determined by scintillation counting, normalized to the
total protein level for that sample and plotted as a percentage of the uptake into non-treated HeLa cells. (C and D) HeLa cells were pre-incubated
with rapamycin (5 or 100nM, as indicated) for 15min before the addition of 4-TU. Total RNA was extracted 30min or 75min after addition of
4-TU and processed to measure levels of labeled rRNA species as described in the ‘Materials and Methods’ section. Levels of puriﬁed labeled rRNA
were compared with those in untreated controls that had been labelled for 45min, data being normalized to the total level of 18S rRNA. Data are
presented as mean±SEM (n=3). The times given below each column indicate the period of 4-TU labeling. (E) HeLa cells were pre-incubated with
4-TU for 4h. After washing with 1  PBS to remove excess 4-TU and transfer to fresh medium, rapamycin (100nM) was added. RNA was extracted
and samples were processed as for Panels C and D. Data are presented and expressed as described in the ‘Materials and Methods’ section, in this
case being normalized to the 45min control and given as mean±SEM (n=3).
2532 Nucleic Acids Research, 2012,Vol.40, No. 6from the fact that AZD8055 decreased the levels of the
12S intermediate while rapamycin did not (Figure 3D).
These differences between the effects of rapamycin and
AZD8055 may reﬂect that fact that the latter compound
inhibits mTORC2 as well as mTORC1 and also blocks
functions of mTORC1 which are insensitive to rapamycin
(25). Similar data were obtained with a different (and
slightly less speciﬁc) mTOR-kinase inhibitor, PP242 (25;
data not shown).
Effects of rapamycin on translation of Rp mRNAs
To assess whether the effect of rapamycin on pre-rRNA
processing was readily reversible, we treated HeLa cells
with rapamycin for 4h and then, in some cases, changed
the medium to one lacking rapamycin, and continued
the cell culture for a further 2h. RNA was extracted and
analysed by northern blot. As seen in Figure 4A, removing
rapamycin led to a loss of the build up of processing
intermediates.
Figure 3. Rapamycin affects pre-rRNA processing in HeLa cells. (A) Schematic diagram of pre-rRNA processing pathways in HeLa cells. Structure
of the primary 47S rRNA transcript containing two internal transcriber spacers (ITS1 and ITS2) and two external transcribed spacers. The 47S
pre-rRNA is processed through intermediate precursors to mature 18S, 28S and 5.8S rRNAs. The locations of the probes used are shown (ITS1 and
ITS2). (B and D) effects of rapamycin and AZD8055 (each used at 100nM) on rRNA processing in serum-fed cells. Northern hybridization of total
RNA from HeLa cells after treatment with rapamycin or actinomycin D (20ng/ml). After 2–6h treatment (as indicated), total RNA was extracted
and subjected to northern blotting analysis for pre-rRNA species. Membranes were hybridized with the ITS1 and ITS2 probes and probes for 18S
and 28S rRNAs. The asterisk indicates cross-reaction with 28S rRNA and the vertical line denotes that these are non-adjacent lanes from the same
gel/northern blot. (C and E) Ratios of different pre-rRNA species. Bar graphs show signal quantiﬁcation using a phosphorimager and the bars
indicate the ratios of 30S to 21S and 32S to 12S after rapamycin or actinomycin D treatment.
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and their synthesis is modulated by mTORC1 signaling:
they are encoded by mRNAs that contain a 50 tract of
pyrimidines (50 TOP), which modulates their translational
efﬁciency, such that rapamycin impairs their recruitment
into polysomes when serum-starved cells are stimulated
with serum (27). Thus, it was possible that inhibiting
mTORC1 signaling affected rRNA processing by
depleting the levels of Rps, especially in the nucleolus
where rRNA in processed. We ﬁrst tested whether
rapamycin’s effect on pre-rRNA processing was
readily reversible, by removing rapamycin from cells
after 4h treatment and allowing them to ‘recover’ for a
further 2h.
We also assessed the effects of rapamycin treatment and
‘recovery’ on the protein synthesis machinery and on
translation of selected 50 TOP mRNAs encoding Rps.
As shown in Figure 4B, rapamycin treatment of HeLa
cells grown in serum caused only a modest decrease in
the levels of active polyribosomes (and a rise in the
levels of ‘free’ subunits; especially clear for 60S
subunits). Removal of rapamycin led to a substantial,
but not quite complete, recovery. Gradient fractions
were analyzed by northern blot for the RpS6 and RpS19
mRNAs and also the b-actin mRNA which is not a
50 TOP message and therefore acts as a ‘negative
control’. Neither addition nor removal of rapamycin
affected the distribution of the b-actin mRNA between
polysomal and non-polysomal fractions (Figure 4C;
quantiﬁed in Figure 4D). In contrast, rapamycin caused
a clear, but only partial, shift of the Rp mRNAs from
large polysomes into smaller polysomes and
non-polysomal material. Overall, the amount of the Rp
mRNAs associated with polysomes decreased only
slightly (from 50% of total being associated with poly-
somes to about 40%; Figure 4D). Removal of rapamycin
allowed a recovery in this, although the effect was incom-
plete (Figure 4C and D). The fact that the changes in Rp
mRNA translation caused by rapamycin are small in
serum-fed cells, and that recovery is only partial, seems
to contrast with the strong inhibition of rRNA processing
caused by rapamycin, and the complete recovery seen after
removal of rapamycin (Figure 4A).
While these data do not allow us to rule out that
changes in Rp levels underlie the effects on rapamycin
on rRNA processing, they suggest that they are unlikely
to play a major role in them. It is perhaps more likely that
alterations in the activity (and phosphorylation) of nucle-
olar components involved in rRNA processing account
for this.
Inhibiting mTORC1 does not induce disruption of the
nucleolus
The nucleolus is the site of rRNA transcription, rRNA
processing and ribosome assembly. Thus, rapamycin
might interfere with rRNA processing simply by
inducing the disruption of nucleoli. To assess this, we
ﬁrst used immunoﬂuorescence to study the localization
of B23 (nucleophosmin) and BOP1 (block of proliferation
1), both of which are nucleolar proteins involved in rRNA
processing (28,29). TOPRO (4-[3-(3-methyl-2(3H)-benzo-
thiazolylidene)]-1-[3-(trimethylamminio)propyl]-, diiodide)
was used to stain DNA and thus the nuclei; nucleoli are
visible as darker areas within nuclei (yellow arrowheads;
Figure 5). Actinomycin D, which at low concentrations
only inhibits Pol I, does not cause complete loss of
nucleoli as they are still visible against the background
nuclear staining. However, it did cause marked disaggre-
gation or redistribution of BOP1 and B23 away from
nucleoli so they appear spread across the nucleoplasm
(Figure 5). In contrast, rapamycin had little effect on the
distribution of B23 and BOP1 (Figure 5), although they
did appear slightly more diffuse than in untreated cells.
Overall it seems that unlike actinomycin D, rapamycin
has, at most, only a modest effect on overall nucleolar
integrity.
mTORC1 is localized to the nucleolus
Given that mTORC1 signaling affects the transcription
and the processing of rRNA, both of which occur in
nucleoli, it was important to ascertain whether compo-
nents of this pathway were present in the nucleolus. We
studied this by subcellular fractionation followed by
western blot, rather than by ectopic (over)expression of,
e.g. GFP-tagged proteins, as this would likely perturb the
stoichiometry and likely the dynamics/distribution of,
e.g. mTOR complexes. We detected mTOR and the
mTORC1-speciﬁc component raptor in the nucleolar
fraction as well as the cytoplasmic and nuclear ones
(Figure 6A and B). This shows that mTORC1 is present
in the cellular locales where mTORC1-dependent tran-
scription and processing of rRNA occur. This is consistent
with the ﬁndings that (30,31) mTOR is associated with the
(nucleolar) Pol I-transcribed genes.
We also asked whether rapamycin altered the nucleolar
levels of mTOR and other proteins. Rapamycin completely
blockedthephosphorylationofnucleolarRpS6,conﬁrming
that it inhibits mTORC1 signaling in this compartment
(Figure 6B). It caused a modest decrease in the levels of
B23 and UBF in the nucleolus. We normalized the data to
levels of histone H3 (Figure 6C). Although rapamycin also
affected them (Figure 6B), the change was small; it may
reﬂect the alterations in nucleolar morphology seen in
Figure 5. Figure 6C reveals that the effect of rapamycin
on the amount of nucleolar mTOR was much greater that
its effect on either UBF or B23, and thus that the effect of
rapamycin on the nucleolar localization is rather selective,
not a general effect on all nucleolar proteins.
The S6 kinases (S6Ks 1 and 2) are key downstream
targets of mTORC1 that are implicated in ribosome bio-
genesis [reviewed in (32)]. We were unable to detect S6K1
within the nuclei or nucleoli of HeLa cells (Figure 6D),
although a trace of S6K2 was evident on long exposure
(Figure 6E). Our data for S6K1 apparently contrast with
the recent ﬁndings that S6K1 is found in the nucleus when
phosphorylated at the mTORC1 site, Thr389 (33,34),
which were performed in a different cell type. It may be
that nuclear levels of S6K1 are simply too low to detect.
The ribosomal protein RpS6 in HeLa cells was also found
2534 Nucleic Acids Research, 2012,Vol.40, No. 6in the nucleolus (as expected since this is the site of
ribosome assembly): rapamycin decreased this, likely
due to inhibition of new RpS6 synthesis, reﬂecting the
fact that the translation of its mRNA is inhibited by
rapamycin (Figure 4).
DISCUSSION
Our ﬁndings demonstrate that, in addition to controlling
the transcription of rRNA and the translation of the
mRNAs that encode ribosomal proteins, mTORC1 signal-
ing also regulates the processing of pre-rRNAs in human
Figure 4. Effect of rapamycin and its removal on ribosome distribution. HeLa cells were incubated with 100nM rapamycin for 4h and then the
medium was replaced with fresh medium without the inhibitor for 2h before the lysis. (A) Total RNA was extracted and subjected to northern blot
analysis for pre-rRNA species. The membrane was hybridized with probes ITS1, ITS2, 18S and 28S as previously described. (B) Polysomal proﬁle
after rapamycin removal of HeLa cells. The polysomal and non-polysomal fractions are indicated. (C) Northern blot analysis of cytoplasmic RNA
extracts from each fraction of sucrose gradient and analyzed with indicated probes (RpS6, RpS19 and b-actin). (D) Quantiﬁcation of the signals is
reported as a linear plot of percentage of mRNAs in each fraction.
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ribosome biogenesis—rRNA transcription, pre-rRNA
processing and the synthesis of ribosomal proteins. Such
coordinated control over ribosome production makes
clear physiological sense and is also consistent with the
importance of ribosome production for cell growth and
proliferation, cellular processes that are positively
regulated by mTORC1 signaling.
We show that inhibition of mTORC1 by rapamycin
interferes with at least distinct stages in pre-rRNA
processes, the conversion of 30S pre-rRNA to the 21S
intermediate and the processing of 32S rRNA, the precur-
sor of the 28S and 5.8S rRNAs. AZD8055, a selective
mTOR kinase inhibitor, appears to have additional
effects pointing to roles for rapamycin-insensitive
outputs from mTORC1 (25) or perhaps a role for
mTORC2 in pre-rRNA processing. It remains to be estab-
lished how mTORC1 promotes pre-rRNA processing.
Interestingly, rapamycin has also been shown to impair
pre-rRNA processing in budding yeast (35), indicating
that control of this process by (m)TORC1 emerged early
during eukaryotic evolution.
Since some Rps participate in the processing of rRNA
(36) and rapamycin inhibits the synthesis [reviewed in (4)]
of Rps, it was possible the changes in the levels of newly
made r-proteins might be responsible for the effects
of rapamycin on rRNA processing, as recently described
in yeast (37). Since there are about 80 different ribosomal
proteins, it is not feasible to examine the potential involve-
ment of each of them in the effects of mTORC1 inhibition
on pre-rRNA processing all of them. Effects of rapamycin
on the translation of the 50-TOP mRNAs were quite
modest. This contrasts with data from budding yeast
where even very brief treatment with rapamycin (15min)
drastically decreased Rp synthesis (37), perhaps reﬂecting
the steep fall in Rp mRNA levels caused by rapamycin in
this species [which probably arises because TORC1
promotes transcription of Rp genes in yeast, whereas it
does not do so in mammals (35)]. We also studied a
possible role for RpS19, a protein that is mutated in
Diamond-Blackfan anaemia, a condition which is
associated with impaired ribosome biogenesis including
the accumulation of early rRNA processing intermediates
(36). This indicates a key role for RpS19 in rRNA pro-
cessing. However, overexpression of RpS19 did not
overcome the defects in rRNA processing caused by
rapamycin, indicating that the effects of mTOR inhibition
cannot be attributed solely to possible changes in levels of
this Rp (data not shown). Thus additional events are im-
portant in the control of rRNA processing downstream of
mTORC1.
Our ﬁnding that mTORC1 is located in the nucleolus
suggested a second potential mechanism by which
rapamycin might affect rRNA processing; i.e. that
affects the amount of mTORC1 associated with nucleoli.
To study this, cells were pre-treated with rapamycin prior
to fractionation. Rapamycin completely blocked the phos-
phorylation of RpS6 at Ser235/236 and Ser240/244
[the latter sites being speciﬁc targets for the S6 kinases
(21)], showing that it is effective in inhibiting mTORC1
Figure 5. Rapamycin treatment induces a partial redistribution of B23 but not of BOP1 into the nucleoplasm. HeLa cells were treated for 2h with
rapamycin or actinomycin D, and then ﬁxed, permeabilized and analyzed by immunoﬂuorescence with monoclonal anti-B23 (red) or anti-BOP1
(green). Cell nuclei were visualized by TO-PRO3 staining. Yellow arrowheads indicate the darker intranuclear regions corresponding to nucleoli.
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(Figure 6A). Rapamycin did not affect the distribution
of GAPDH or lamin B (cytoplasmic and nuclear
markers, respectively), but did cause a marked decrease
in the amount of mTOR associated with nucleolar
fraction, but not the nuclear fraction (Figure 6A and B).
This suggests that rapamycin causes the relocation of
mTORC1 away from sites of active pre-rRNA processing,
which may provide a mechanism by which it can regulate
this process. The decrease in nucleolar mTOR levels may
also play a role in the inhibitory effects of rapamycin on
Pol I-mediated transcription (2). It was clearly possible
that the mTORC1 substrates S6K1 or (since we ﬁnd it
in the nucleus, Figure 6E, albeit at low levels) S6K2
might play a role in rRNA processing. However,
overexpressing S6K1 or S6K2 did not protect rRNA
processing from inhibition by rapamycin, although it did
eliminate its effect on RpS6 phosphorylation (data not
shown). Clearly, further work is required to dissect the
molecular events that underlie the control of pre-rRNA
processing by mTORC1.
The observation that low levels of rapamycin (the
minimum required to effectively inhibit mTORC1 signal-
ing) impair uridine uptake suggests that mTORC1 signal-
ing may promote the transport of nucleosides into
mammalian cells; this would make good physiological
sense as they are precursors for RNA and thus ribosome
production, but further work is required to establish
whether this effect genuinely reﬂects a role for mTORC1
signaling (as suggested by the fact that the inhibition
caused by 5nM rapamycin was almost maximal) or is an
indirect or ‘off-target’ effect of this compound.
Figure 6. Cytoplasmic, nuclear and nucleolar distribution of mTORC1 and other proteins in HeLa cells. (A and B) Subcellular localization of
endogenous mTOR components or targets and other proteins in HeLa cells. Where indicated, cells were treated with rapamycin (100nM). The total,
cytoplasmic, nuclear and nucleolar fractions were isolated after 2h treatment and analyzed by western blot. GAPDH (cytoplasmic), lamin B (nuclear)
and B23 and UBF (nucleolar) were used as fractionation markers. (C) Bar graph shows signal quantiﬁcation of nucleolar on the total fraction of
mTOR, B23 and UBF after 2h treatment with rapamycin. (D and E) Localization of endogenous S6K1 and S6K2 in HeLa cells. Since the signal for
S6K2 is weak, a longer exposure is also shown for the nucleolar fraction.
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